×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MNPR – monopar therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MNPR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/2
08:00 am
mnpr
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
Medium
Report
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
2/23
08:04 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
2/2
08:05 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
1/29
08:27 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $100.00 price target on the stock.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $100.00 price target on the stock.
1/21
10:12 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
1/14
08:04 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
1/9
07:00 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2025
08:00 am
mnpr
monopar therapeutics inc.
MISS
Report
3.8%
monopar therapeutics inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/4
05:26 pm
mnpr
Form 4 Monopar Therapeutics For: Mar 02 Filed by: Rodriguez Susan
Low
Report
Form 4 Monopar Therapeutics For: Mar 02 Filed by: Rodriguez Susan
3/4
05:25 pm
mnpr
Form 3 Monopar Therapeutics For: Mar 02 Filed by: Rodriguez Susan
Low
Report
Form 3 Monopar Therapeutics For: Mar 02 Filed by: Rodriguez Susan
3/2
08:01 am
mnpr
Form 8-K Monopar Therapeutics For: Mar 02
Medium
Report
Form 8-K Monopar Therapeutics For: Mar 02
2/17
04:39 pm
mnpr
Form SCHEDULE 13G/A Monopar Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
Medium
Report
Form SCHEDULE 13G/A Monopar Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
2/6
09:55 am
mnpr
Form SCHEDULE 13G/A Monopar Therapeutics Filed by: ASTRAZENECA PLC
Low
Report
Form SCHEDULE 13G/A Monopar Therapeutics Filed by: ASTRAZENECA PLC
1/30
02:32 pm
mnpr
Form SCHEDULE 13D/A Monopar Therapeutics Filed by: Tactic Pharma LLC
Low
Report
Form SCHEDULE 13D/A Monopar Therapeutics Filed by: Tactic Pharma LLC
1/30
02:31 pm
mnpr
Form 4 Monopar Therapeutics For: Jan 28 Filed by: Robinson Chandler
Low
Report
Form 4 Monopar Therapeutics For: Jan 28 Filed by: Robinson Chandler
1/5
03:46 pm
mnpr
Form 4 Monopar Therapeutics For: Dec 31 Filed by: Robinson Chandler
Low
Report
Form 4 Monopar Therapeutics For: Dec 31 Filed by: Robinson Chandler
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/18
Monopar Therapeutics Inc. Announces Pricing of Initial Public Offering
217.4%
12/19 Form 424B4 Monopar Therapeutics 3.1%
4/29 Form DEFA14A Monopar Therapeutics 3.0%
4/18 Monopar Therapeutics Inc. (NASDAQ: MNPR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.00 price target on the stock. 1.5%
2/19 Monopar Therapeutics Inc. (NASDAQ: MNPR) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $42.00 price target on the stock. 1.4%
12/19 Form 424B4 Monopar Therapeutics 3.1%
4/29 Form DEFA14A Monopar Therapeutics 3.0%
4/18 Monopar Therapeutics Inc. (NASDAQ: MNPR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.00 price target on the stock. 1.5%
2/19 Monopar Therapeutics Inc. (NASDAQ: MNPR) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $42.00 price target on the stock. 1.4%
TOP News Decliners
12/20
Monopar Therapeutics Inc. Announces Full Exercise of Over-Allotment by Underwriters
-19.5%
2/20 Form 4 Monopar Therapeutics For: Jan 31 Filed by: STARR CHRISTOPHER M -9.5%
2/18 Monopar Therapeutics Receives Orphan Drug Designation from the European Commission for Camsirubicin in the Treatment of Soft Tissue Sarcoma -7.5%
1/13 Form 424B5 Monopar Therapeutics -5.7%
1/3 Form S-8 Monopar Therapeutics -4.1%
3/27 Q4/2019 12/31/2019 EPS -0.130 ZacksConsensus N/A ActVsEst N/A - N/A -2.9%
1/7 Form 8-K Monopar Therapeutics For: Jan 07 -1.4%
4/1 Form 4 Monopar Therapeutics For: Mar 31 Filed by: Anderson Raymond -1.0%
4/30 Monopar Therapeutics Inc. (NASDAQ: MNPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -0.3%
4/21 Monopar Therapeutics Inc. (NASDAQ: MNPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -0.2%
2/20 Form 4 Monopar Therapeutics For: Jan 31 Filed by: STARR CHRISTOPHER M -9.5%
2/18 Monopar Therapeutics Receives Orphan Drug Designation from the European Commission for Camsirubicin in the Treatment of Soft Tissue Sarcoma -7.5%
1/13 Form 424B5 Monopar Therapeutics -5.7%
1/3 Form S-8 Monopar Therapeutics -4.1%
3/27 Q4/2019 12/31/2019 EPS -0.130 ZacksConsensus N/A ActVsEst N/A - N/A -2.9%
1/7 Form 8-K Monopar Therapeutics For: Jan 07 -1.4%
4/1 Form 4 Monopar Therapeutics For: Mar 31 Filed by: Anderson Raymond -1.0%
4/30 Monopar Therapeutics Inc. (NASDAQ: MNPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -0.3%
4/21 Monopar Therapeutics Inc. (NASDAQ: MNPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -0.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: